The analysis showed a high rate of sustained virologic response (SVR) in patients receiving boceprevir-based combination therapy in this study of 595 treatment-naive patients with chronic hepatitis C
This randomized, double-blind, placebo-controlled trial is being conducted in HIV infected patients with the potential to offer an important drug free break in their current antiretroviral therapy. The
The application seeks approval to treat symptoms of seasonal allergic rhinitis and perennial allergic rhinitis. The new formulation is patent pending. Six Phase III studies evaluating efficacy and
EpiCept will receive approximately $2.65 million in net proceeds from the offering. Rodman & Renshaw, a subsidiary of Rodman & Renshaw Capital Group, acted as the exclusive placement
Escitalopram oxalate is indicated for depression and generalized anxiety disorders and is marketed under the brand name Lexapro. Based on product development results, the company is preparing to
The study, to be performed in collaboration with the US Centers for Disease Control and Prevention (CDC) Rabies program, is scheduled to begin soon. This study will expand
According to Oncure Medical, the acquisition expands the company’s national network of radiation oncology centers to 36 centers in three states. Deloitte Corporate Finance acted as exclusive financial
Under the agreement, Invitrogen will provide access to its extensive human and mouse gene libraries for use by Lentigen for the development of ready-to-use lentiviral particles that deliver
Woojin Lee, president and founder of Cambridge Endo, said: “With the ability to articulate, rotate and lock, our Autonomy Lapro-Angle instruments vastly improve the surgeon’s dexterity in tight
Serenity’s drug candidate will be delivered using Cpex’s patented drug delivery technology. Serenity believes the drug targets a potential worldwide market of $2-$3 billion. The collaboration between Serenity
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.